Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

Omeros announced that the company submitted a New Drug Application (NDA) to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery. OMS302, added to ...

SEATTLE, Jan. 22, 2013 /PRNewswire/ – Omeros Corporation (OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical ...

enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study Results show that enVista Envy IOLs deliver excellent visual performance, ...

(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Nov. 14, 2003--eyeonics inc.(TM), the developer of a new class of visual enhancement systems, today announced that it has received FDA approval to market the ...

RxSight reported preliminary Q4 results, capping off a record year for growth where sales climbed by approximately 82%. The company is capturing strong demand for its adjustable intraocular lens ...